White & Case litigation partner who reps Gilead moves to Cahill Gordon & Reindel

Firm adds to its New York office with the appointment of ANDA expert as a partner in litigation group | Represented clients such as Gilead, Sanofi-Aventis, and Bristol-Myers Squibb in high-stakes cases.

Cahill Gordon & Reindel has added Colleen Tracy James to its New York office as a partner in the litigation group.

The move, announced January 29, follows the recent appointment of Peter Armenio, as co-chair of the life sciences patent litigation and IP litigation practices on January 24.

James, previously a partner at White & Case, will serve as co-chair of the life sciences patent litigation practice.

She brings her expertise in patent infringement litigation, and US Patent and Trademark Office Patent Trial and Appeal Board proceedings to the firm.

Gerald Flattmann Jr, co-chair of Cahill’s life sciences patent litigation practice and co-chair of the firm’s IP litigation group, said: “Colleen’s impressive track record and her broad client base make her one of the industry’s most sought-after practitioners in this space.”

Some of James work includes representing Gilead against Teva in an ANDA litigation relating to Viread, Atripla and Truvada products, representing Sanofi-Aventis in an ANDA litigation relating to Sanofi's Eloxatin product, and representing Bristol-Myers Squibb against Repligen and Bristol-Myers Squibb against Zymogenetics in two patent infringement suits relating to Bristol-Myers Squibb’s drug Orencia.

Herbert Washer, chair of Cahill's executive committee, said James' clients have been “among the global leaders in life sciences”, making the firm “proud” she had chosen Cahill to continue that success.

James' previous clients also include Allergan (now part of AbbVie), Takeda, and AstraZeneca.

David Januszewski, chair of Cahill’s litigation department said: “Colleen is not only one of the industry’s best high-stakes patent litigators, she also guides clients through licensing and due diligence.”

Speaking on the move, James said: “Cahill has made clear that it sees IP as a powerful opportunity and an engine of growth, and I could not be more excited to help turn that vision into a reality, joining the incredible team already in place.”

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox